Assessing the efficacy and safety of dapagliflozin in patients with HFrEF
April 22, 2021
Can the use of dapagliflozin, in addition to guideline-directed medical therapy, improve patient-reported outcomes and health-related quality of life in patients with heart failure and reduced ejection fraction (HFrEF)?
Dapagliflozin may cut risk of HF hospitalization in patients with type 2 diabetes
March 25, 2021
What is the Food and Drug Administration–approved indication for dapagliflozin (Farxiga)?
COVID-19 can cause atypical thyroid inflammation
March 24, 2021
Patients with thyroid abnormalities during acute COVID-19, or who develop such symptoms, should have thyroid function checked every 6 months for a year.
High obesity rates in Southern states magnify COVID threats
March 19, 2021
At least 29 states have green-lighted obesity for inclusion in the first phases of the COVID-19 vaccine rollout. That could overwhelm government efforts and heighten competition for scarce doses.
‘Major update’ of BP guidance for kidney disease; treat to 120 mm Hg
March 16, 2021
“[Chapter one] of the guidelines is devoted to blood pressure measurement ... if [targeting] 120 [mm Hg systolic], the emphasis is on 120 measured properly.”
Don’t discontinue osteoporosis meds for COVID-19 vaccines, expert guidance says
March 11, 2021
Recommendations help physicians distinguish between a reaction to the vaccine and a reaction to medication.
Inpatient sodium imbalances linked to adverse COVID-19 outcomes
March 11, 2021
Hypernatremia during hospitalization was associated with increased COVID-19 mortality and to a greater need for ventilatory support.
Call to action on obesity amid COVID-19 pandemic
March 9, 2021
Hundreds of thousands of deaths worldwide from COVID-19 could have been avoided if obesity rates were lower; call for people with obesity to be included in priority lists for COVID-19 vaccination.
Heart failure redefined with new classifications, staging
March 8, 2021
Heart failure terminology gets a landmark reno, with a new universal definition, revised stages of development and progression, and updated LVEF classifications.
Thirteen percent of patients with type 2 diabetes have major ECG abnormalities
March 2, 2021
ECGs from more than 8,000 Dutch patients with type 2 diabetes, most without known cardiovascular disease, show that major abnormalities are not unusual.